Improving the therapeutic efficiency of noncoding RNAs in cancers using targeted drug delivery systems

Wapinski, 2011, Long noncoding RNAs and human disease, Trends Cell Biol., 21, 354, 10.1016/j.tcb.2011.04.001 Mercer, 2009, Long non-coding RNAs: insights into functions, Nat. Rev. Genet., 10, 155, 10.1038/nrg2521 Matsui, 2017, Non-coding RNAs as drug targets, Nat. Rev. Drug Discov., 16, 167, 10.1038/nrd.2016.117 Gutschner, 2012, The hallmarks of cancer: a long non-coding RNA point of view, RNA Biol., 9, 703, 10.4161/rna.20481 Anastasiadou, 2017, Non-coding RNA networks in cancer, Nat. Rev. Cancer, 18, 5, 10.1038/nrc.2017.99 Mattick, 2006, Non-coding RNA, Hum. Mol. Genet., 15, R17, 10.1093/hmg/ddl046 Mendell, 2005, MicroRNAs: critical regulators of development, cellular physiology and malignancy, Cell Cycle, 4, 1179, 10.4161/cc.4.9.2032 He, 2004, Erratum: MicroRNAs: small RNAs with a big role in gene regulation, Nat. Rev. Genet., 5, 522, 10.1038/nrg1379 Esquela-Kerscher, 2006, Oncomirs:microRNAs with a role in cancer, Nat. Rev. Cancer, 6, 259, 10.1038/nrc1840 Hammond, 2007, MicroRNAs as tumor suppressors, Nat. Genet., 39, 582, 10.1038/ng0507-582 Nicoloso, 2009, MicroRNAs - the micro steering wheel of tumour metastases, Nat. Rev. Cancer, 9, 293, 10.1038/nrc2619 Esteller, 2011, Non-coding RNAs in human disease, Nat. Rev. Genet., 12, 861, 10.1038/nrg3074 Shi, 2013, Long non-coding RNAs: a new frontier in the study of human diseases, Cancer Lett., 339, 159, 10.1016/j.canlet.2013.06.013 Yang, 2015, MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer, Sci. Rep., 5, 8509, 10.1038/srep08509 Ganesh, 2013, In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles, J. Control. Release, 172, 699, 10.1016/j.jconrel.2013.10.016 Yang, 2015, Cluster of differentiation 44 targeted hyaluronic acid based nanoparticles for MDR1 siRNA delivery to overcome drug resistance in ovarian cancer, Pharm. Res., 32, 2097, 10.1007/s11095-014-1602-1 Ma, 2013, On the classification of long non-coding RNAs, RNA Biol., 10, 924, 10.4161/rna.24604 Lin, 2008, Translational control by a small RNA: dendritic BC1 RNA targets the eukaryotic initiation factor 4A helicase mechanism, Mol. Cell. Biol., 28, 3008, 10.1128/MCB.01800-07 Parrott, 2011, The evolution and expression of the snaR family of small non-coding RNAs, Nucleic Acids Res., 39, 1485, 10.1093/nar/gkq856 Beltran, 2008, A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial–mesenchymal transition, Genes Dev., 22, 756, 10.1101/gad.455708 Cesana, 2011, A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA, Cell, 147, 358, 10.1016/j.cell.2011.09.028 Sumazin, 2011, An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma, Cell, 147, 370, 10.1016/j.cell.2011.09.041 Gong, 2011, lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3′ UTRs via Alu elements, Nature, 470, 284, 10.1038/nature09701 Salmena, 2011, ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?, Cell, 146, 353, 10.1016/j.cell.2011.07.014 Tay, 2011, Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs, Cell, 147, 344, 10.1016/j.cell.2011.09.029 Faghihi, 2008, Expression of a noncoding RNA is elevated in Alzheimer’s disease and drives rapid feed-forward regulation of β-secretase, Nat. Med., 14, 723, 10.1038/nm1784 Wang, 2009, MicroRNA-based therapeutics for cancer, BioDrugs, 23, 15, 10.2165/00063030-200923010-00002 Heneghan, 2010, MiRNAs as biomarkers and therapeutic targets in cancer, Curr. Opin. Pharmacol., 10, 543, 10.1016/j.coph.2010.05.010 Sakamoto, 2017, Non-coding RNAs are promising targets for stem cell-based cancer therapy, Noncoding RNA Res., 2, 283 Ozcan, 2015, Preclinical and clinical development of siRNA-based therapeutics, Adv. Drug Deliv. Rev., 87, 108, 10.1016/j.addr.2015.01.007 Chakraborty, 2017, Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine, Mol. Ther. Nucleic Acids, 8, 132, 10.1016/j.omtn.2017.06.005 Kim, 2016, Recent progress in development of siRNA delivery vehicles for cancer therapy, Adv. Drug Deliv. Rev., 104, 61, 10.1016/j.addr.2016.06.011 Lares, 2010, RNAi and small interfering RNAs in human disease therapeutic applications, Trends Biotechnol., 28, 570, 10.1016/j.tibtech.2010.07.009 Ozpolat, 2014, Liposomal siRNA nanocarriers for cancer therapy, Adv. Drug Deliv. Rev., 66, 110, 10.1016/j.addr.2013.12.008 Bumcrot, 2006, RNAi therapeutics: a potential new class of pharmaceutical drugs, Nat. Chem. Biol., 2, 711, 10.1038/nchembio839 Selvam, 2017, Therapeutic potential of chemically modified siRNA: recent trends, Chem. Biol. Drug Des., 90, 665, 10.1111/cbdd.12993 Krützfeldt, 2005, Silencing of microRNAs in vivo with ‘antagomirs’, Nature, 438, 685, 10.1038/nature04303 Oh, 2009, A highly effective and long-lasting inhibition of miRNAs with PNA-based antisense oligonucleotides, Mol. Cells, 28, 341, 10.1007/s10059-009-0134-8 Weinstein, 2010, RNAi nanomedicines: challenges and opportunities within the immune system, Nanotechnology, 21, 232001, 10.1088/0957-4484/21/23/232001 Wang, 2010, Delivery of siRNA therapeutics: barriers and carriers, The AAPS Journal, 12, 492, 10.1208/s12248-010-9210-4 Mukherjee, 1997, Endocytosis, Physiol. Rev., 77, 759, 10.1152/physrev.1997.77.3.759 Zuckerman, 2015, Clinical experiences with systemically administered siRNA-based therapeutics in cancer, Nat. Rev. Drug Discov., 14, 843, 10.1038/nrd4685 Shen, 2014, Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics, Theranostics, 4, 487, 10.7150/thno.8263 Ewe, 2017, Liposome-polyethylenimine complexes (DPPC-PEI lipopolyplexes) for therapeutic siRNA delivery in vivo, Nanomedicine, 13, 209, 10.1016/j.nano.2016.08.005 Xiang, 2017, Enhancing siRNA-based cancer therapy using a new pH-responsive activatable cell-penetrating peptide-modified liposomal system, Int. J. Nanomed., 12, 2385, 10.2147/IJN.S129574 Sun, 2019, Delivery of siRNA using folate receptor-targeted pH-sensitive polymeric nanoparticles for rheumatoid arthritis therapy, Nanomedicine, 20, 102017, 10.1016/j.nano.2019.102017 Busch, 2016, Prospective and therapeutic screening value of non-coding RNA as biomarkers in cardiovascular disease, Annals of translational medicine, 4, 10.21037/atm.2016.06.06 Adams, 2014, Aberrant regulation and function of microRNAs in cancer, Curr. Biol., 24, R762, 10.1016/j.cub.2014.06.043 Zeliadt, 2014, Big pharma shows signs of renewed interest in RNAi drugs, Nat. Med., 20, 109, 10.1038/nm0214-109 van Rooij, 2012, Developing microRNA therapeutics, Circ. Res., 110, 496, 10.1161/CIRCRESAHA.111.247916 Stenvang, 2012, Inhibition of microRNA function by antimiR oligonucleotides, Silence, 3, 1, 10.1186/1758-907X-3-1 Henry, 2010, miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines, Biochem. Biophys. Res. Commun., 403, 120, 10.1016/j.bbrc.2010.10.130 Pereira, 2013, Delivering the promise of miRNA cancer therapeutics, Drug Discov. Today, 18, 282, 10.1016/j.drudis.2012.10.002 Shah, 2016, microRNA therapeutics in cancer - an emerging concept, EBioMedicine, 12, 34, 10.1016/j.ebiom.2016.09.017 Nielsen, 1994, Peptide nucleic acid (PNA). A DNA mimic with a peptide backbone, Bioconjug. Chem., 5, 3, 10.1021/bc00025a001 Fabani, 2008, miR-122 targeting with LNA/2′-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA--peptide conjugates, RNA, 14, 336, 10.1261/rna.844108 Misso, 2014, Mir-34: a new weapon against cancer?, Mol. Ther. Acids, 3, e195, 10.1038/mtna.2014.47 Pirollo, 2008, Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo, Clin. Cancer Res., 14, 2190, 10.1158/1078-0432.CCR-07-1951 Trang, 2011, Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice, Mol. Ther., 19, 1116, 10.1038/mt.2011.48 Kasinski, 2015, A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer, Oncogene, 34, 3547, 10.1038/onc.2014.282 Woodrow, 2009, Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA, Nat. Mater., 8, 526, 10.1038/nmat2444 Rinn, 2012, Genome regulation by long noncoding RNAs, Annu. Rev. Biochem., 81, 145, 10.1146/annurev-biochem-051410-092902 Smaldone, 2010, BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers, Curr. Opin. Mol. Ther., 12, 607 Fatemi, 2014, De-repressing LncRNA-targeted genes to upregulate gene expression: focus on small molecule therapeutics, Mol. Ther. Acids, 3, e196, 10.1038/mtna.2014.45 Rettig, 2012, Progress toward in vivo use of siRNAs-II, Mol. Ther., 20, 483, 10.1038/mt.2011.263 Kurreck, 2002, Design of antisense oligonucleotides stabilized by locked nucleic acids, Nucleic Acids Res., 30, 1911, 10.1093/nar/30.9.1911 Tsang, 2007, MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals, Mol. Cell., 26, 753, 10.1016/j.molcel.2007.05.018 Trang, 2010, Regression of murine lung tumors by the let-7 microRNA, Oncogene, 29, 1580, 10.1038/onc.2009.445 Bandi, 2011, miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner, Mol. Cancer, 10, 55, 10.1186/1476-4598-10-55 Herranz, 2010, MicroRNAs and gene regulatory networks: managing the impact of noise in biological systems, Genes Dev., 24, 1339, 10.1101/gad.1937010 Babar, 2012, Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma, Proc. Natl. Acad. Sci. U. S. A., 109, E1695, 10.1073/pnas.1201516109 Kasinski, 2012, miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma, Cancer Res., 72, 5576, 10.1158/0008-5472.CAN-12-2001 Liu, 2013, Downregulation of GAS5 promotes bladder cancer cell proliferation, partly by regulating CDK6, PLoS One, 8, e73991, 10.1371/journal.pone.0073991 Guo, 2015, GAS5 inhibits gastric cancer cell proliferation partly by modulating CDK6, Oncol. Res. Treat., 38, 362, 10.1159/000433499 Yin, 2014, Long noncoding RNA GAS5 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer, Med. Oncol., 31, 253, 10.1007/s12032-014-0253-8 Yang, 2014, Down-regulation of mir-221 and mir-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1, PLoS One, 9, e98833, 10.1371/journal.pone.0098833 Wang, 2015, Effects of microRNA-221/222 on cell proliferation and apoptosis in prostate cancer cells, Gene, 572, 252, 10.1016/j.gene.2015.07.017 Stahlhut, 2012, miR-1 and miR-206 regulate angiogenesis by modulating VegfA expression in zebrafish, Development, 139, 4356, 10.1242/dev.083774 Kuehbacher, 2007, Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis, Circ. Res., 101, 59, 10.1161/CIRCRESAHA.107.153916 Cimmino, 2005, miR-15 and miR-16 induce apoptosis by targeting BCL2, Proc. Natl. Acad. Sci. U. S. A., 102, 13944, 10.1073/pnas.0506654102 Meng, 2007, MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer, Gastroenterology, 133, 647, 10.1053/j.gastro.2007.05.022 De Mattos-Arruda, 2015, MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients, Oncotarget, 6, 37269, 10.18632/oncotarget.5495 Yigit, 2013, Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasis, Oncogene, 32, 1530, 10.1038/onc.2012.173 Ma, 2010, Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor mode, Nat. Biotechnol., 28, 341, 10.1038/nbt.1618 Liu, 2012, miR-10b promotes cell invasion through RhoC-AKT signaling pathway by targeting HOXD10 in gastric cancer, Int. J. Oncol., 40, 1553 Xue, 2015, Lipid-based nanocarriers for RNA delivery, Curr. Pharm. Des., 21, 3140, 10.2174/1381612821666150531164540 Gascón, 2013, Non-viral delivery systems in gene therapy, 3 Ghosh, 2013, A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells, Biomaterials, 34, 807, 10.1016/j.biomaterials.2012.10.023 Alhasan, 2014, Exosome encased spherical nucleic acid gold nanoparticle conjugates as potent MicroRNA regulation agents, Small, 10, 186, 10.1002/smll.201302143 Gao, 2017, Nrf-2-driven long noncoding RNA ODRUL contributes to modulating silver nanoparticle-induced effects on erythroid cells, Biomaterials, 130, 14, 10.1016/j.biomaterials.2017.03.027 Mouraviev, 2016, Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer, Prostate Cancer Prostatic Dis., 19, 14, 10.1038/pcan.2015.48 Oh, 2009, siRNA deliverysystems forcancer treatment, Adv. Drug Deliv. Rev., 61, 850, 10.1016/j.addr.2009.04.018 Monteiro, 2014, Liposomes in tissue engineering and regenerative medicine, J. R. Soc. Interface, 11, 10.1098/rsif.2014.0459 Kanasty, 2013, Delivery materials for siRNA therapeutics, Nat. Mater., 12, 967, 10.1038/nmat3765 Gabizon, 1994, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes, Cancer Res., 54, 987 Gabizon, 1991, Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin, Br. J. Cancer, 64, 1125, 10.1038/bjc.1991.476 Allen, 2013, Liposomal drug delivery systems: from concept to clinical applications, Adv. Drug Deliv. Rev., 65, 36, 10.1016/j.addr.2012.09.037 Bouchie, 2013, First microRNA mimic enters clinic, Nat. Biotechnol., 31, 577, 10.1038/nbt0713-577 Chen, 2010, Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer, J. Biol. Chem., 285, 22639, 10.1074/jbc.M110.125906 Brito, 2014, A cationic nanoemulsion for the delivery of next-generation RNA vaccines, Mol. Ther., 22, 2118, 10.1038/mt.2014.133 Fang, 2008, Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC), Eur. J. Pharm. Biopharm., 70, 633, 10.1016/j.ejpb.2008.05.008 Chen, 2018, RNA interference-based therapy and its delivery systems, Cancer Metastasis Rev., 37, 107, 10.1007/s10555-017-9717-6 Gary, 2007, Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery, J. Control. Release, 121, 64, 10.1016/j.jconrel.2007.05.021 Wagner, 2011, Polymers for siRNA delivery: inspired by viruses to be targeted, dynamic, and precise, Acc. Chem. Res., 45, 1005, 10.1021/ar2002232 Dehousse, 2010, Development of pH-responsive nanocarriers using trimethylchitosans and methacrylic acid copolymer for siRNA delivery, Biomaterials, 31, 1839, 10.1016/j.biomaterials.2009.11.028 Sun, 2008, Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery, Biomaterials, 29, 4348, 10.1016/j.biomaterials.2008.07.036 Sau, 2018, A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy, Drug Discov. Today, 23, 1344, 10.1016/j.drudis.2018.03.003 Alsaab, 2017, PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, andclinical outcome, Front. Pharmacol., 8, 561, 10.3389/fphar.2017.00561 Wickens, 2017, Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy, Drug Discov. Today, 22, 665, 10.1016/j.drudis.2016.12.009 Bhise, 2017, Nanomedicine for cancer diagnosis and therapy: advancement, success and structure--activity relationship, Ther. Deliv., 8, 1003, 10.4155/tde-2017-0062 Riaz, 2018, Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a review, Int. J. Mol. Sci., 19, 195, 10.3390/ijms19010195 Torchilin, 2010, Passive and active drug targeting: drug delivery to tumors as an example, Handb. Exp. Pharmacol., 197, 3, 10.1007/978-3-642-00477-3_1 Li, 2017, Be active or not: the relative contribution of active and passive tumor targeting of nanomaterials, Nanotheranostics, 1, 346, 10.7150/ntno.19380 Maeda, 2013, The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo, Adv. Drug Deliv. Rev., 65, 71, 10.1016/j.addr.2012.10.002 Costa, 2018, Micelle-like nanoparticles as siRNA and miRNA carriers for cancer therapy, Biomed. Microdevices, 20, 59, 10.1007/s10544-018-0298-0 Low, 2008, Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases, Acc. Chem. Res., 41, 120, 10.1021/ar7000815 Wang, 2018, CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer, Nanomedicine, 14, 1441, 10.1016/j.nano.2018.04.004 Yu, 2013, Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells, Nanoscale, 5, 178, 10.1039/C2NR32145A Kim, 2018, Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer, Drug Deliv., 25, 1394, 10.1080/10717544.2018.1480672 Alsaab, 2017, Folate decorated nanomicelles loaded with a potent curcumin analogue for targeting retinoblastoma, Pharmaceutics, 9, E15, 10.3390/pharmaceutics9020015 Xia, 2018, siRNA-loaded selenium nanoparticle modified with hyaluronic acid for enhanced hepatocellular carcinoma therapy, Int. J. Nanomed., 13, 1539, 10.2147/IJN.S157519 Li, 2009, Targeted delivery of doxorubicin using stealth liposomes modified with transferrin, Int. J. Pharm., 373, 116, 10.1016/j.ijpharm.2009.01.023 Koshkaryev, 2012, Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes, Cancer Biol. Ther., 13, 50, 10.4161/cbt.13.1.18871 Ye, 2016, CPP-assisted intracellular drug delivery, what is next?, Int. J. Mol. Sci., 17, 1892, 10.3390/ijms17111892 Chen, 2012, Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats, Int. J. Nanomed., 7, 3803, 10.2147/IJN.S33541 Meng, 2011, Integrin-targeted paclitaxel nanoliposomes for tumor therapy, Med. Oncol., 28, 1180, 10.1007/s12032-010-9621-1 Slaby, 2017, Therapeutic targeting of non-coding RNAs in cancer, Biochem. J., 474, 4219, 10.1042/BCJ20170079 Sau, 2017, Advances in antibody-drug conjugates: a new era of targeted cancer therapy, Drug Discov. Today, 22, 1547, 10.1016/j.drudis.2017.05.011 Sau, 2018, Multifunctional nanoparticles for cancer immunotherapy: a groundbreaking approach for reprogramming malfunctioned tumor environment, J. Control. Release, 274, 24, 10.1016/j.jconrel.2018.01.028 Manjappa, 2011, Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor, J. Control. Release, 150, 2, 10.1016/j.jconrel.2010.11.002 Mamot, 2005, Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo, Cancer Res., 65, 11631, 10.1158/0008-5472.CAN-05-1093 Lee, 2015, Inhibition of pulmonary cancer progression by epidermal growth factor receptor-targeted transfection with Bcl-2 and survivin siRNAs, Cancer Gene Ther., 22, 335, 10.1038/cgt.2015.18 Eloy, 2017, Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy, Eur. J. Pharm. Biopharm., 115, 159, 10.1016/j.ejpb.2017.02.020 Park, 2002, Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery, Clin. Cancer Res., 8, 1172 Hatakeyama, 2007, Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes, Int. J. Pharm., 342, 194, 10.1016/j.ijpharm.2007.04.037 Gosk, 2008, VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo, Biochim. Biophys. Acta Biomembr., 1778, 854, 10.1016/j.bbamem.2007.12.021 Sivakumar, 2018, Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 11, e1543, 10.1002/wnan.1543 Li, 2018, Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy, Int. J. Nanomed., 13, 1241, 10.2147/IJN.S158290 Edmonds, 2016, MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer, J. Clin. Invest., 126, 349, 10.1172/JCI82720 Zhang, 2016, Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression, Nat. Commun., 7, 11702, 10.1038/ncomms11702 Adams, 2016, miR-34a silences c-SRC to attenuate tumor growth in triple-negative breast cancer, Cancer Res., 76, 927, 10.1158/0008-5472.CAN-15-2321 Babar, 2012, Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma, Proc. Natl. Acad. Sci. U. S. A., 109, E1695, 10.1073/pnas.1201516109 Yao, 2013, pHLIP peptide targets nanogold particles to tumors, Proc. Natl. Acad. Sci. U. S. A., 110, 465, 10.1073/pnas.1219665110 Arun, 2016, Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss, Genes Dev., 30, 34, 10.1101/gad.270959.115 Yin, 2015, Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer, Tumor Biol., 36, 4851, 10.1007/s13277-015-3139-2 Choung, 2006, Chemical modification of siRNAs to improve serum stability without loss of efficacy, Biochem. Biophys. Res. Commun., 342, 919, 10.1016/j.bbrc.2006.02.049